Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Sen, Banibrata; Peng, Shaohua; Tang, Ximing; Erickson, Heidi S; Galindo, Hector; Mazumdar, Tuhina; Stewart, David J; Wistuba, Ignacio; Johnson, Faye M

Sen, Banibrata; Peng, Shaohua; Tang, Ximing; Erickson, Heidi S; Galindo, Hector; Mazumdar, Tuhina; Stewart, David J; Wistuba, Ignacio; Johnson, Faye M.

Affiliation

Sen B; Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Sci Transl Med ; 4(136): 136ra70, 2012 May 30.

Article in En | MEDLINE | ID: mdl-22649091

Subject(s)

Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Protein Kinase Inhibitors/therapeutic use; Proto-Oncogene Proteins B-raf/genetics; Pyrimidines/therapeutic use; Thiazoles/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Cell Line, Tumor; Cell Proliferation/drug effects; Dasatinib; Humans; Mutation; Protein Kinase Inhibitors/pharmacology; Pyrimidines/pharmacology; Thiazoles/pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Thiazoles / Proto-Oncogene Proteins B-raf / Protein Kinase Inhibitors / Lung Neoplasms Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2012 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google